研究单位：[1]ImmuneOnco Biopharmaceuticals (Shanghai) Inc.[2]Anhui Provincial Hospital,Hefei,Anhui,China[3]China-Japan Friendship Hospita,Beijing,Beijing,China[4]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China[5]First Hospital of Lanzhou University,Lanzhou,Gansu,China[6]The First Affiliated Hospital of Guangxi Medical University,Nanning,Gaungxi,China[7]Nanfang Hospital, Southern Medical University,Guangzhou,Guangdong,China[8]Shenzhen Second People''s Hospital,Shenzhen,Guangdong,China[9]Zhujiang Hospital of Southern Medical University,Zhujiang,Guangdong,China[10]Guangdong Provincial People''s Hospital,Guangzhou,Guangzhou,China[11]Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China[12]Affiliated Hospital of Hebei University,Shijiazhuang,Hebei,China[13]The Second Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[14]Harbin First Hospital,Harbin,Heilongjiang,China[15]First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[16]Henan Cancer Hospital,Zhengzhou,Henan,China[17]Henan Provincial People''s Hospital,Zhengzhou,Henan,China[18]The First Affiliated Hospital of Henan University of Science and Technology,Zhengzhou,Henan,China[19]Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China[20]Zhongnan Hospital Affiliated to Wuhan University,Wuhan,Hubei,China[21]Xiangyang Central Hospital,Xiangyang,Hubei,China[22]Xiangya Hospital Central South University,Changsha,Hunan,China[23]Changzhou First People''s Hospital,Changzhou,Jiangsu,China[24]Jiangsu Province Hospital,Nanjing,Jiangsu,China[25]Zhongda Hospital affiliated to Southeast University,Nanjing,Jiangsu,China[26]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China[27]Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,China[28]Jiangsu Subei People''s Hospital,Yangzhou,Jiangsu,China[29]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[30]The First Hospital of Jilin University,Changchun,Jilin,China[31]Shengjing Hospital of China Medical University,Shenyang,Liaoning,China[32]The First Hospital of China Medical University,Shenyang,Liaoning,China[33]Qilu Hospital of Shandong University,Jinan,Shandong,China[34]Shaanxi Provincial People''s Hospital,Xi''an,Shanxi,China[35]Sichuan Provincial People''s Hospital,Chengdu,Sichuan,China[36]Yibin Second People''s Hospital,Yibin,Sichuan,China[37]Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College[38],Tianjin,Tianjin,China,300020[39]The First Affiliated Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China[40]The Second Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China[41]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003[42]Ningbo First Hospital,Ningbo,Zhejiang,China[43]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,China[44]Peking University People''s Hospital,Beijing,China[45]Tianjin People''s Hospital,Tianjin,China
研究目的：
This study is a randomized, controlled, double-blind, multicenter, phase Ⅲ clinical study to evaluate the efficacy of IMM01(timdarpacept) in combination with azacitidine versus placebo in combination with azacitidine in patients with newly diagnosed chronic leukemia monocytic (CMML1-2).Primary endpoint are Complete remission rate and Overall survival.
